Epix Pharmaceuticals president and head of research and development Dr. Andrew Uprichard has resigned to pursue other opportunities.
Uprichard had been president and head of research and development at the Lexington, MA-based MR contrast developer since 2006. He will continue to assist Epix as a consultant, according to the company.
Related Reading
Epix to resubmit NDA for Vasovist, April 24, 2008
Epix reaches agreement with FDA over Vasovist, February 1, 2008
Epix to raise $16.3 million, November 12, 2007
Epix receives FDA response, June 19, 2007
Epix posts big Q1 loss, May 9, 2007
Copyright © 2008 AuntMinnie.com